BCR and diffuse large B-cell lymphoma: Given the pathogenic role of the My-T-BCR supercomplex, combination of mTOR inhibitors with BCR inhibitors could be used in DLBCL depending on the My-T-BCR supercomplex (28), and BTK inhibitor ibrutinib and mTOR inhibitor are synergistic in suppressing the growth the xenografts of TMD8, which is dependent on the My-T-BCR supercomplex, supporting combinational use of BTK inhibitors and mTOR inhibitors in My-T-BCR supercomplex positive DLBCLs (28).